Clinical momentum Healionics is actively advancing STARgraft through human studies with 24-month results being presented at CiDA conferences, indicating ongoing clinical validation and opportunities to engage nephrology and vascular access specialists around trial milestones.

Funding traction With multiple rounds totaling around 27M in funding, including federal SBIR support and a recent Series A-3, there is demonstrated investor confidence and potential for partnerships or co-development deals to accelerate commercialization.

Patented platform A robust IP position with 36 patents issued or pending on STARgraft and STAR biomaterial suggests defensible technology and collaboration opportunities with larger medical device manufacturers seeking safer dialysis access solutions.

Strategic partnerships Participation in high-profile industry events and recognition at Investor Capital Expo, along with a clear focus on reducing occlusion and infection, positions Healionics as a potential partner for established dialysis device makers seeking innovative vascular grafts.

Market readiness Revenue is in the small to mid-market range with a clear path to scale; combined with a lean team and cloud-based tech stack, this presents opportunities for OEM collaborations, distribution deals, or licensing agreements to broaden market reach.